June 28, 2012—Human protein products manufacturer Octapharma USA has announced an initiative to make its octagam 5% immune globulin intravenous (IGIV) therapy for primary immune deficiency widely available to 340B covered entities.
“Octapharma is committed to providing therapies to treat life-threatening conditions to all patients, including those who are treated in facilities that have historically faced challenges accessing IGIV,” Octapharma USA President Flemming Nielsen said in a June 26 prepared statement.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)